Loading patent…
AssigneeIdera Pharmaceuticals, Inc.
InventorsEkambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
Estimating the term…
The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
An immune regulatory oligonucleotide (IRO) compound selected from 5′-C*TATC*TGUC*G1TTC*TC*TGU-3′ and 5′-CTATCTGUC*G2TTCTCTGU-3′, wherein G1=7-deaza-dG;
Dependencies are inferred from the claim text.